Women’s Health Today—June 24, 2026

This biweekly Women’s Health video recap highlights funding and care delivery innovations, AI-enabled prevention initiatives, biomarker advances, and emerging clinical data across gynecologic and breast cancers.

Dive deeper

In Today’s Newsletter

💍 Clair Health and June Health women’s health funding [1] [US/Canada • 18 Jun 2026]

https://www.mobihealthnews.com/news/clair-health-raises-116m-womens-hormone-monitoring-wearable-and-more-funding-news
Context: Clair Health is developing a jewelry-inspired wrist wearable to monitor estrogen, progesterone, LH, FSH, and PdG in real time.
Key point: Clair Health raised $11.6M; June Health raised CAD$2.4M for a women’s health benefits platform.
Implication: Signals pipeline investment and modality expansion.

🧠 FamilyWell Health Menopause Hub launch [2] [US • 18 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/18/3314216/0/en/familywell-health-launches-menopause-hub-setting-the-standard-for-behavioral-health-in-midlife-care.html
Context: The Menopause Hub includes a free clinical white paper and Menopause Behavioral Health Certification.
Key point: FamilyWell Health launched resources focused on behavioral and mental health during perimenopause and menopause.
Implication: May expand screening, initiation, and follow-up at scale.

🩺 EBSCO–AWHONN point-of-care nursing partnership [3] [US • 11 Jun 2026]

https://www.prnewswire.com/news-releases/ebsco-clinical-decisions-and-awhonn-partner-to-drive-clinical-excellence-in-womens-health-obstetric-and-neonatal-nursing-302798278.html
Context: AWHONN experts will review specialized nursing content in EBSCO’s Dynamic Health platform.
Key point: The partnership aims to support women’s health, obstetric, and neonatal nurses with validated evidence-based content.
Implication: Could streamline point-of-care decisions and standardize clinical practice.

📱 Nivi–MSD HPV awareness and prevention initiative [4] [India/Indonesia/Thailand • 16 Jun 2026]

https://www.prnewswire.com/news-releases/nivi-inc-and-msd-collaborate-to-expand-hpv-disease-awareness-and-cervical-cancer-prevention-through-ai-powered-platform-302799457.html
Context: Nivi’s conversational AI platform will deliver localized HPV education, risk assessments, and referrals.
Key point: Nivi and MSD announced a collaboration beginning in India, Indonesia, and Thailand.
Implication: May expand screening, initiation, and follow-up at scale.

🧬 Dostarlimab 6-year GARNET data in dMMR/MSI-H endometrial cancer [5] [20 Jun 2026]

https://www.onclive.com/view/dostarlimab-provides-long-term-benefits-in-dmmr-msi-h-endometrial-cancer
Context: Phase 1 GARNET cohort A1 evaluated dostarlimab monotherapy in advanced or recurrent dMMR/MSI-H endometrial cancer.
Key point: Six-year follow-up showed durable responses, deepening complete responses, and no new safety signals.
Implication: May influence prescriber choice and payer reviews pending full data.

🎯 Mocertatug rezetecan BEHOLD-1 ADC data [6] [17 Jun 2026]

https://www.onclive.com/view/mocertatug-rezetecan-drives-rapid-deep-responses-in-platinum-resistant-ovarian-and-recurrent-advanced-endometrial-cancer
Context: BEHOLD-1 tested mocertatug rezetecan, a B7-H4-directed ADC, in platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.
Key point: Interim data showed dose-related confirmed response activity, with phase 3 doses selected for both indications.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Zymeworks ZW191 FRα-targeting ADC data [7] [Canada • 14 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/14/3311472/0/en/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-adc-zw191-at-esmo-gynaecological-cancers-congress-2026.html
Context: ZW191 is a folate receptor alpha-targeting ADC in Phase 1 testing for gynecologic cancers.
Key point: Zymeworks reported activity in platinum-resistant ovarian cancer, including FRα-positive and FRα-negative tumors.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Delphi Diagnostics EAI breast cancer publication [8] [US • 22 Jun 2026]

https://www.prnewswire.com/news-releases/delphi-diagnostics-announces-new-publication-confirming-eai-predicts-benefit-from-weekly-paclitaxel-in-hrher2-breast-cancer-302806818.html
Context: The GEICAM/9906 analysis evaluated EAI in HR+/HER2− breast cancer using a prospective-retrospective design.
Key point: Delphi Diagnostics said EAI identified patients more likely to benefit from weekly paclitaxel-containing adjuvant chemotherapy.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Women’s health funding is moving into longitudinal monitoring, employer benefits, and AI-enabled care navigation.
Menopause and midlife behavioral health are becoming more structured care categories.
Gynecologic oncology ADC pipelines are expanding across ovarian and endometrial cancers.
Biomarker tools such as EAI may shift chemotherapy decisions from recurrence risk alone toward regimen selection.
AI-enabled awareness programs may help close cervical cancer prevention gaps in high-burden markets.

📚 View the full Women’s health archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Clair Health building?

Clair Health is developing a wrist-worn continuous hormone monitor for women, designed to track estrogen, progesterone, LH, FSH, and PdG in real time. [1]

What does FamilyWell Health’s Menopause Hub include?

It includes a free clinical white paper for providers and a Menopause Behavioral Health Certification for coaches and behavioral health professionals. [2]

How will Nivi and MSD support HPV awareness?

Nivi’s conversational AI platform will provide localized HPV education, risk assessments, and referrals to vaccination and screening services in India, Indonesia, and Thailand. [4]

What did the GARNET data show for dostarlimab?

Six-year follow-up in dMMR/MSI-H advanced or recurrent endometrial cancer showed durable antitumor activity and no new safety signals. [5]

What is mocertatug rezetecan?

Mocertatug rezetecan is a B7-H4-directed ADC being evaluated in platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer. [6]

What is Delphi Diagnostics’ EAI intended to predict?

EAI is a genomic assay that Delphi said may predict benefit from weekly paclitaxel-containing adjuvant chemotherapy in HR+/HER2− breast cancer. [8]

Entities / Keywords

Clair Health, continuous hormone monitor, estrogen, progesterone, LH, FSH, PdG
June Health, women’s health benefits, fertility, menopause, mental health
FamilyWell Health, Menopause Hub, MBH-C, menopause behavioral health
EBSCO Clinical Decisions, Dynamic Health, AWHONN, obstetric nursing, neonatal nursing
Nivi, MSD, Merck Sharp & Dohme, HPV, cervical cancer prevention, conversational AI
Dostarlimab, Jemperli, GARNET, dMMR/MSI-H endometrial cancer
Mocertatug rezetecan, Mo-Rez, BEHOLD-1, B7-H4 ADC, PROC, endometrial cancer
Zymeworks, ZW191, FRα ADC, platinum-resistant ovarian cancer
Delphi Diagnostics, Endocrine Activity Index, EAI, GEICAM/9906, HR+/HER2− breast cancer, weekly paclitaxel